Egypt Hepatitis C treatment drug market
is anticipated to register a lucrative growth over the forecast period,
2023-2027. Hepatitis C is an infection caused by a virus that mainly attacks
the liver and leads to inflammation. This infection is spread by the contact
with contaminated blood or other bodily fluids. Hepatitis can be acute or
chronic, but type C of Hepatitis is one of the most hazardous and hard to
treat. The market growth can be attributed to the growing prevalence of
hospital-acquired infections (HAIs) that a patient generally gets while
receiving treatment from a clinic or hospital from a healthcare professional.
This has resulted in the development of Hepatitis C treatment drugs and new
product launches, such as the launch of fixed-dose combinations. Moreover, the
rising coordinated efforts for the research and development of powerful
medications to treat Hepatitis C is creating a positive impact on the market.
Moreover, the leading market players are continuously focusing on utilizing
innovative technologies for the development of medications to enhance the
effectiveness and efficiency of the medicines for the treatment of Hepatitis C
patients.
Introduction of Advanced Treatment Drugs
to Fuel the Market Growth
Introduction of advanced Hepatitis C
drugs is leading to a considerable reduction of patients suffering from the
infection. Moreover, with the recent approvals of Sofosbuvir (Sovaldi) and Simeprevir
(Olysio), the healthcare professionals and patients have started to recognize
that Hepatitis C can be cured without Interferons. Moreover, the new treatment
drugs have better efficacy, are safe, and have minimal adverse effects. Hence,
increasing awareness towards advanced Hepatitis C drugs and their greater
availability across online and retail channels are adding to the market growth.
Government Initiatives to Accelerate the
Market Growth
The adoption of new treatment drugs is
increasing at a fast pace due to the several initiatives taken by the
government to educate the patients regarding the new therapeutics. This is
providing a positive outlook to the Egypt market. In addition, the governments
of several countries are allocating funds to the concerned authorities to
provide hepatitis C treatment drugs at a subsidized rate, which is also
strengthening the market growth. Furthermore, the increasing number of clinical
trials and successful drug clearances have supplemented the overall growth of
the hepatitis C market. For instance, since 2014, Egypt has increased the
healthcare services to eliminate HCV, which is followed by the President Abdel Fatah al-Sisi's
initiative to treat 1 million HCV-infected patients annually and reduce
the risk of mortality and morbidity. Such programs are anticipated to provide
lucrative growth opportunities to the Egypt hepatitis C treatment drugs
market.
DOWNLOAD FREE SAMPLE REPORT
Market Segmentation
The Egypt Hepatitis C treatment drug
market is segmented by disease type, drug class, distribution channel, competitive
landscape, and regional distribution. Based on the disease type the market is
differentiated between acute and chronic. By drug class the market is segmented
into combination therapy, protease inhibitors, polymerase inhibitors,
immunomodulators, antiviral medications, and others. Based on the distribution
channel, the market is fragmented into hospital pharmacies, retail pharmacies, and
online pharmacies. The market analysis also studies the regional segmentation,
divided among Cairo, Alexandria, Giza, Qalyubia, Port
Said, Suez, and Rest of Egypt.
Company Profile
GlaxoSmithKline,
Plc., Gilead Sciences, Inc., Johnson & Johnson, AbbVie, Inc., Merck &
Co., Inc., Bristol-Myers Squibb Company, and F. Hoffmann-La Roche AG are the
leading market players of the Egypt Hepatitis C treatment drug market.
|
Attribute
|
Details
|
|
Base Year
|
2021
|
|
Historical Data
|
2017 –
2020
|
|
Estimated Year
|
2022
|
|
Forecast Period
|
2023
– 2027
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027
|
|
Report coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments covered
|
·
Disease Type
·
Drug Class
·
Distribution Channel
|
|
Regional Scope
|
Cairo,
Alexandria, Giza, Qalyubia, Port Said, Suez, and Rest of Egypt.
|
|
Key companies profiled
|
GlaxoSmithKline, Plc., Gilead Sciences, Inc., Johnson &
Johnson, AbbVie, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company,
and F. Hoffmann-La Roche AG
|
|
Customization scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery Format
|
PDF
and Excel through Email (We can also provide the editable version of the
report in PPT/Word format on special request)
|
Report Scope:
In this report, Egypt Hepatitis C
treatment drug market has been segmented into following categories, in addition
to the industry trends which have also been detailed below:
- Egypt Hepatitis C Treatment Drug
Market, By Disease Type:
o
Acute
o
Chronic
- Egypt Hepatitis C Treatment Drug
Market, By Drug Class:
o
Combination
Therapy
o
Protease
Inhibitors
o
Polymerase
Inhibitors
o
Immunomodulators
o
Antiviral
Medications
o
Others
- Egypt Hepatitis C Treatment Drug Market,
By Distribution Channel:
o
Hospital
Pharmacies
o
Retail
Pharmacies
o
Online
Pharmacies
·
Egypt
Hepatitis C Treatment Drug Market, By Region:
o
Cairo
o
Alexandria
o
Giza
o
Qalyubia
o
Port
Said
o
Suez
o
Rest of
Egypt.
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in Egypt Hepatitis C Treatment Drug
Market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following
customization options are available for the report:
Company
Information
- Detailed analysis and profiling of additional
market players (up to five).
Egypt Hepatitis C Treatment Drug Market is an upcoming report to be
released soon. If you wish an early delivery of this report or want to confirm
the date of release, please contact us at [email protected]